AKT1 and neoplasm: Loss of FAK and treatment with a FAK inhibitor (PF-562271) suppressed tumor growth and the invasion ability of ES cells in vivo and in vitro by suppressing Crkl-associated substrate (CAS) activity and the AKT/mTOR pathway (Crompton et al., 2013).